Preliminary anticancer evaluation of new Pd(II) complexes bearing NNO donor ligands

Shazia Hussain, Shabeeb Hussain, M. Naveed Zafar, Irfan Hussain, Faizullah Khan, Ehsan Ullah Mughal, Muhammad Nawaz Tahir

Research output: Contribution to journalArticlepeer-review


In this study we presented a novel series of NNO tridentate ligands generating imino, amido and oxo donor pocket for Pd(II) coordination. All the compounds were meticulously characterized by elemental analysis and advanced spectroscopic techniques, including FTIR, proton and carbon NMR. The synthesized compounds underwent rigorous evaluation for their potential as anti-cancer agents, utilizing the aggressive breast cancer cell lines MDA-MB (ATCC) and MCF-7 as a crucial model for assessing growth inhibition in cancer cells. Remarkably, the MTT assay unveiled the robust anti-cancer activity for all palladium complexes against MDA-MB-231 and MCF-7 cells. Particularly, complex [Pd(L1)(CH3CN)] exhibited exceptional potency with an IC50 value of 25.50 ± 0.30 µM (MDA-MB-231) and 20.76 ± 0.30 µM (MCF-7), compared to respective 27.00 ± 0.80 µM and 24.10 ± 0.80 µM for cisplatin, underscoring its promising therapeutic potential. Furthermore, to elucidate the mechanistic basis for the anti-cancer effects, molecular docking studies on tyrosine kinases, an integral target in cancer research, were carried out. The outcome of these investigations further substantiated the remarkable anticancer properties inherent to these innovative compounds. This research offers a compelling perspective on the development of potent anti-cancer agents rooted in the synergy between ligands and Pd(II) complexes and presenting a promising avenue for future cancer therapy endeavors.

Original languageEnglish
Article number101915
JournalSaudi Pharmaceutical Journal
Issue number1
Publication statusPublished - Jan 2024
Externally publishedYes


  • Breast cancer cell line
  • MCF-10A
  • MCF-7
  • MDA-MB-231
  • MTT assays
  • NNO-ligands
  • Pd(II)
  • Tyrosine Kinase


Dive into the research topics of 'Preliminary anticancer evaluation of new Pd(II) complexes bearing NNO donor ligands'. Together they form a unique fingerprint.

Cite this